Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Bladder Cancer

Free Subscription 02.02.2026 1 Animals (Basel) 1 Bioengineering (Basel) 1 Biol Sex Differ 1 Biosens Bioelectron 1 Bladder Cancer 1 BMC Urol 1 Can Urol Assoc J 1 Cancer 4 Cancers (Basel) 1 Cell 1 Cell Oncol (Dordr) 1 Clin Cancer Res 1 Curr Med Chem 1 Curr Top Med Chem 1 Cytotechnology 1 Discov Oncol 1 Eur Urol 1 F1000Res 2 Front Immunol 1 Front Mol Biosci 2 Front Oncol 1 Front Urol 1 Genes Chromosomes Cancer 1 Healthcare (Basel) 1 IEEE Trans Biomed Eng 2 Int J Biol Macromol 1 Int J Clin Oncol 1 Int J Mol Sci 2 Int J Urol 2 Int Urol Nephrol 1 J Clin Med 1 J Egypt Natl Canc Inst 1 J Liq Biopsy 1 J Med Internet Res 1 J Proteome Res 1 Life (Basel) 3 Medicina (Kaunas) 1 Medicine (Baltimore) 1 Oncol Res 1 Oncologist 1 Pharmacol Res Perspect 1 Protein Pept Lett 1 Research (Wash D C) 1 Semin Oncol Nurs 1 Transl Oncol 1 Urol Oncol 1 World J Urol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Animals (Basel)

1. PIRES I, Files R
   Silent Threats: A Narrative Review of Urinary Bladder Cancer in Dogs and Cats-Epidemiology and Risk Factors.
   Animals (Basel). 2026;16:217.
   PubMed         Abstract available
   
   

   
   Bioengineering (Basel)

2. MOHAMED AA, AbdulAzeem Y, Almudaifer AI, ZainEldin H, et al
   Explainable Computational Imaging for Precision Oncology: An Interpretable Deep Learning Framework for Bladder Cancer Histopathology Diagnosis.
   Bioengineering (Basel). 2025;13:4.
   PubMed         Abstract available
   
   

   
   Biol Sex Differ

3. WANG Y, Bhandary P, Moore JH, Li X, et al
   Integrative microRNA and transcriptome analysis reveals sex-specific molecular divergence in human bladder cancer.
   Biol Sex Differ. 2026 Jan 23. doi: 10.1186/s13293-026-00829.
   PubMed         Abstract available
   
   

   
   Biosens Bioelectron

4. LUTY M, Szydlak R, Pabijan J, Ovreeide IH, et al
   Identification of glycosylation-related changes in migratory and mechanical properties of bladder cancer cells.
   Biosens Bioelectron. 2026;298:118410.
   PubMed         Abstract available
   
   

   
   Bladder Cancer

5. HARMON JF, Santos E, Johnson-Pais TL, Leach RJ, et al
   Association of CCL2/CCR2 gene polymorphisms and bladder cancer risk in a hispanic-rich US population.
   Bladder Cancer. 2026;12:23523735261417401.
   PubMed         Abstract available
   
   

   
   BMC Urol

6. NEBIOGLU A, Basaranoglu M, Bozlu M, Tek M, et al
   Effects of dutasteride with Bacillus Calmette-Guerin therapy on recurrence, progression, metastasis, and survival in non-muscle invasive bladder cancer: a retrospective single-center study.
   BMC Urol. 2026 Jan 28. doi: 10.1186/s12894-026-02059.
   PubMed        
   
   

   
   Can Urol Assoc J

7. MARCQ G, Dahm P, Maisch P
   En-bloc resection: Evidence and uncertainty Re: Comparative effectiveness of en-bloc resection techniques vs. conventional transurethral resection for non-muscle-invasive bladder cancer: A systematic review and meta-analysis.
   Can Urol Assoc J. 2026;20:E80-E81.
   PubMed        
   
   

   
   Cancer

8. BHATTACHARYA R, Kponee-Shovein K, Gao Y, Song Y, et al
   Event-free survival and complete response rate as surrogate endpoints for overall survival in high-risk non-muscle-invasive bladder cancer: A meta-analysis of bacillus Calmette-Guerin-naive or -remote cases.
   Cancer. 2026;132:e70220.
   PubMed         Abstract available
   
   

   
   Cancers (Basel)

9. SANDHU K, Hopkins DT, Newton M, Sathianathen N, et al
   Oligometastatic Bladder Cancer: Current Definitions, Diagnostic Challenges, and Evolving Therapeutic Strategies.
   Cancers (Basel). 2026;18:189.
   PubMed         Abstract available
   
   
10. PITOUT A, Mazeaud C, Blondeau A, Salleron J, et al
    Sarcopenia Predicts Mortality in Bladder Cancer with Neoadjuvant Chemotherapy: A Multicenter Study.
    Cancers (Basel). 2026;18:222.
    PubMed         Abstract available
    
    
11. PACKIAM VT, Ghodoussipour S, Konety BR, Ahmadi H, et al
    Impact of Computational Histology AI Biomarkers on Clinical Management Decisions in Non-Muscle Invasive Bladder Cancer: A Multi-Center Real-World Study.
    Cancers (Basel). 2026;18:249.
    PubMed         Abstract available
    
    
12. CERIA F, Muhammad G, Del Giudice F, Ibrahim Y, et al
    Unveiling the Female Factor: Gender-Based Differences in Outcomes and Survival Following Radical Cystectomy for Bladder Cancer.
    Cancers (Basel). 2026;18:308.
    PubMed         Abstract available
    
    

    
    Cell

13. SHI WY, Liu KJ, Esfahani MS, Mach KE, et al
    Field-effect-informed urine liquid biopsy for bladder cancer.
    Cell. 2026 Jan 27:S0092-8674(25)01503-X. doi: 10.1016/j.cell.2025.
    PubMed         Abstract available
    
    

    
    Cell Oncol (Dordr)

14. ZHANG WW, Qu HR, Du XS, Sun SJ, et al
    SREBP2-RAB11A-ZDHHC20 axis orchestrates FGFR3 palmitoylation and membrane retention to drive bladder cancer progression.
    Cell Oncol (Dordr). 2026;49:30.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

15. EPSTEIN IB, Odogiyon A, Berg S, Otani Y, et al
    ctDNA dynamics and recurrence patterns after organ-sparing trimodality therapy for bladder cancer.
    Clin Cancer Res. 2026 Jan 26. doi: 10.1158/1078-0432.CCR-25-3712.
    PubMed         Abstract available
    
    

    
    Curr Med Chem

16. CHEN Y, Zhu H, Lao M, Ding G, et al
    Exploring ZPLD1 as a Prognostic Indicator and Therapeutic Target in Bladder Cancer.
    Curr Med Chem. 2026 Jan 15. doi: 10.2174/0109298673413898251122184011.
    PubMed         Abstract available
    
    

    
    Curr Top Med Chem

17. CHEN Y, Lao M, Shen M, Wang Z, et al
    TMIGD2 in Bladder Cancer: A Bioinformatics and Experimental Approach to Understanding its Prognostic and Therapeutic Potential.
    Curr Top Med Chem. 2026 Jan 15. doi: 10.2174/0115680266414071251126071447.
    PubMed         Abstract available
    
    

    
    Cytotechnology

18. SHEN L, Yu C, Wu Y, Chen H, et al
    NFIB suppresses cell migration, invasion and EMT of bladder cancer through the PI3K-AKT signaling pathway.
    Cytotechnology. 2026;78:33.
    PubMed         Abstract available
    
    

    
    Discov Oncol

19. LU Q, Guo J, Xu Y, Cui Y, et al
    RAD54B as a biomarker for prognosis and immunotherapy response in bladder cancer.
    Discov Oncol. 2026 Jan 28. doi: 10.1007/s12672-026-04514.
    PubMed        
    
    

    
    Eur Urol

20. CABRERA C, Buisan O, Servian P
    Reply to the Harry Herr's Letter to the Editor re: Oscar Buisan, Pol Servian, Sonia Pedreno-Lopez, et al. A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guerin Response in Non-muscle-invasive Bladder Canc
    Eur Urol. 2026 Jan 23:S0302-2838(26)00018-7. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    

    
    F1000Res

21. RAHMADI R, Mudhia Arisa Putri U, Herman H, Rachman W, et al
    Case Report: Radical urethrectomy with partial cystectomy and bladder outlet reconstruction in giant female urethral adenocarcinoma infiltrating the bladder: A rare case report.
    F1000Res. 2026;14:741.
    PubMed         Abstract available
    
    

    
    Front Immunol

22. PAN S, Cui W, Lin J, Wang Z, et al
    The infection-microbiome-immunity axis in bladder cancer: mechanistic insights and therapeutic perspectives.
    Front Immunol. 2026;16:1716230.
    PubMed         Abstract available
    
    
23. YUAN Z, Situ M, Ye Y, Zhang J, et al
    Dissecting the role of KLF5: from tumor progression to immune interactions with emphasis on glioma and bladder cancer.
    Front Immunol. 2026;16:1730356.
    PubMed         Abstract available
    
    

    
    Front Mol Biosci

24. SU X, Yu H, Zhang M, Zeng K, et al
    A novel prognostic model based on epithelial cell progression genes identifies OAS1 as a suppressor of bladder cancer aggressiveness.
    Front Mol Biosci. 2026;12:1716130.
    PubMed         Abstract available
    
    

    
    Front Oncol

25. WANG P, Deng J, Wu S
    Modeling and validation of serum miR-18a and miR-122 levels as predictors of recurrence after laparoscopic radical cystectomy procedure for bladder cancer based on nomogram model.
    Front Oncol. 2026;15:1579873.
    PubMed         Abstract available
    
    
26. FENG R, Zhang J, Tao Y, Hou J, et al
    Preoperative inflammation-based immune prognostic nomogram in bladder cancer: a multicenter study.
    Front Oncol. 2026;15:1644747.
    PubMed         Abstract available
    
    

    
    Front Urol

27. HU H, Huang J, Ma L, Zhang S, et al
    Hexaminolevulinate blue light cystoscopy improves bladder cancer detection in comparison to white light cystoscopy: a prospective, comparative, within-patient controlled multicenter phase III bridging study in China.
    Front Urol. 2026;5:1713128.
    PubMed         Abstract available
    
    

    
    Genes Chromosomes Cancer

28. KLUTH M, Plage H, Furlano K, Hofbauer S, et al
    PTEN Deletions Are Associated With Tumor Progression But Unrelated to Patient Prognosis in Muscle-Invasive Urothelial Bladder Carcinomas: A Large Multi-Center Validation Study on 2710 Urothelial Bladder Carcinomas.
    Genes Chromosomes Cancer. 2026;65:e70105.
    PubMed         Abstract available
    
    

    
    Healthcare (Basel)

29. NAN Z, Zhao W, Li S, Yue C, et al
    Unequal Progress in Early-Onset Bladder Cancer Control: Global Trends, Socioeconomic Disparities, and Policy Efficiency from 1990 to 2021.
    Healthcare (Basel). 2026;14:193.
    PubMed         Abstract available
    
    

    
    IEEE Trans Biomed Eng

30. WANG X, Preston A, Aning J, Loizou M, et al
    Early Detection of Bladder Cancer Using Advanced Feature Engineering and Swarm Intelligence Optimization on EHRs.
    IEEE Trans Biomed Eng. 2026;PP.
    PubMed         Abstract available
    
    

    
    Int J Biol Macromol

31. FANG Q, You C, Xiao X, Yang W, et al
    Targeting the WWP2-ASPP2 axis overcomes cisplatin resistance by inhibiting the mevalonate pathway in TP53-mutant bladder cancer.
    Int J Biol Macromol. 2026;343.
    PubMed         Abstract available
    
    
32. CHEN M, Zheng L, Huang D, Wang S, et al
    RBM15/IGF2BP3 promotes immune escape in bladder cancer by enhancing m6A modification of PFKFB4.
    Int J Biol Macromol. 2026 Jan 22:150142. doi: 10.1016/j.ijbiomac.2026.150142.
    PubMed         Abstract available
    
    

    
    Int J Clin Oncol

33. MIKI J, Kimura S, Urabe F, Atsuta M, et al
    Optimizing pelvic lymph node dissection in bladder cancer: obturator focus, pN1 prognosis, and sentinel node feasibility.
    Int J Clin Oncol. 2026 Jan 27. doi: 10.1007/s10147-026-02969.
    PubMed         Abstract available
    
    

    
    Int J Mol Sci

34. JIANG H, Chen Y, Zeng X, Yang R, et al
    The Role of Natural Compounds in Bladder Urothelial Carcinoma Treatment.
    Int J Mol Sci. 2026;27:596.
    PubMed         Abstract available
    
    

    
    Int J Urol

35. FUKUTA K, Sasaki Y, Daizumoto K, Izumi K, et al
    Prognostic Significance of Achieving the Radical Cystectomy-Pentafecta After Neoadjuvant Chemotherapy and Robot-Assisted Radical Cystectomy.
    Int J Urol. 2026;33:e70283.
    PubMed         Abstract available
    
    
36. SHIMIZU S, Osawa T, Sato M, Yamada S, et al
    Validation of the 7-Item Quality of Life Disease-Specific Impact Scale in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Cross-Sectional Study.
    Int J Urol. 2026;33:e70364.
    PubMed         Abstract available
    
    

    
    Int Urol Nephrol

37. OZDEN SB, Bulbul E, Ilki Y, Vural A, et al
    Effect of frailty status and histopathological features on upstaging of non-muscle-invasive bladder cancer: a critical analysis based on machine learning.
    Int Urol Nephrol. 2026 Jan 26. doi: 10.1007/s11255-026-05021.
    PubMed         Abstract available
    
    
38. AYKAC A, Kaya C, Sungur M, Aydin ME, et al
    Holmium laser en?bloc vs bipolar and conventional monopolar TURBT for non?muscle?invasive bladder cancer.
    Int Urol Nephrol. 2026 Jan 24. doi: 10.1007/s11255-026-05023.
    PubMed         Abstract available
    
    

    
    J Clin Med

39. FRYD ND, Albertsen N, Bernth-Andersen S, Ernst A, et al
    The GreenBladder Study: Early Detection of Bladder Cancer in Greenland Using a Urinary Biomarker.
    J Clin Med. 2026;15:761.
    PubMed         Abstract available
    
    

    
    J Egypt Natl Canc Inst

40. KARKEET RM, Sayed-Ahmed MM, Ghaly S, Farouk M, et al
    Comprehensive Evaluation of Bacillus Calmette-Guerin therapy in Non-muscle invasive bladder cancer Egyptian patients: a retrospective cohort study.
    J Egypt Natl Canc Inst. 2026;38:2.
    PubMed        
    
    

    
    J Liq Biopsy

41. NAPPI A, Crocetto F, Conforti P, Sagliocchi S, et al
    Cell-free RNA profiling uncovers non-canonical circulating D2 transcript elevation in Bladder Cancer plasma.
    J Liq Biopsy. 2026;11:100454.
    PubMed         Abstract available
    
    

    
    J Med Internet Res

42. SHIH YC, Wu CY, Huang SW, Tsai CY, et al
    Multimodal Large Language Models for Cystoscopic Image Interpretation and Bladder Lesion Classification: Comparative Study.
    J Med Internet Res. 2026;28:e87193.
    PubMed         Abstract available
    
    

    
    J Proteome Res

43. SILVA TA, Viana LG, Carvalho VM, Bertolla RP, et al
    Proteomic Profiling of Non-Muscle Invasive Bladder Cancer Reveals Potential Biomarkers for Recurrence and Progression Risk.
    J Proteome Res. 2026 Jan 26. doi: 10.1021/acs.jproteome.5c00486.
    PubMed         Abstract available
    
    

    
    Life (Basel)

44. KLATTE T, Bold F, Dengler J, de Martino M, et al
    Trends in the Management of Bladder Cancer with Emphasis on Frailty: A Nationwide Analysis of More Than 49,000 Patients from a German Hospital Network.
    Life (Basel). 2026;16:169.
    PubMed         Abstract available
    
    

    
    Medicina (Kaunas)

45. COJOCARU I, Guliciuc M, Cojocaru E, Serban C, et al
    A Review of the Latest Evidence on Prognostic Factors in Locally Advanced and Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
    Medicina (Kaunas). 2025;62:46.
    PubMed         Abstract available
    
    
46. ALQAISI O, Tai P, Storme G
    Specialized Nursing-Led Interventions for Bladder Cancer Management: A Scoping Review of Evidence and Clinical Outcomes.
    Medicina (Kaunas). 2026;62:185.
    PubMed         Abstract available
    
    
47. NEBIOGLU A, Turhan A, Basaranoglu M, Bozlu M, et al
    Prognostic Significance of Hemogram Parameters in Non-Muscle Invasive Bladder Cancer: A Comprehensive Retrospective Analysis.
    Medicina (Kaunas). 2025;62:51.
    PubMed         Abstract available
    
    

    
    Medicine (Baltimore)

48. CHEN WW, Wu B, Wen X
    Causal association between socioeconomic disparities and tumors of the urinary system: A Mendelian randomization study.
    Medicine (Baltimore). 2026;105:e47216.
    PubMed         Abstract available
    
    

    
    Oncol Res

49. ZHANG X, Zong R, Sun Y, Chen N, et al
    The FN1-ITGB4 Axis Drives Acquired Chemoresistance in Bladder Cancer by Activating FAK Signaling.
    Oncol Res. 2026;34:21.
    PubMed         Abstract available
    
    

    
    Oncologist

50. ZENG D, Liu B, Deng F, Wang Y, et al
    Multidimensional liquid biopsy in bladder cancer: advances in circulating tumor cells, circulating tumor DNA, exosomes, and metabolomics.
    Oncologist. 2026;31:oyaf409.
    PubMed         Abstract available
    
    

    
    Pharmacol Res Perspect

51. CHAN CC, Lee MJ, Su J, Su JJ, et al
    Exploring Pembrolizumab-Induced IM3OS in a Patient With Bladder Cancer.
    Pharmacol Res Perspect. 2026;14:e70212.
    PubMed         Abstract available
    
    

    
    Protein Pept Lett

52. QIU M, Zhang S, Liang J, Chen G, et al
    Prolyl 4-Hydroxylase Beta Peptide Promotes Invasion, Migration, and Epithelial-Mesenchymal Transition through Activation of the Claudin-1/ AMPK/TGF-beta1 Pathway in Bladder Cancer Cells.
    Protein Pept Lett. 2026 Jan 22. doi: 10.2174/0109298665418763251124051527.
    PubMed         Abstract available
    
    

    
    Research (Wash D C)

53. HE Y, Xie J, Zhong S, Zhan C, et al
    A Deep Learning-Generated Mixed Tumor-Stroma Ratio for Prognostic Stratification and Multi-omics Profiling in Bladder Cancer.
    Research (Wash D C). 2026;9:1053.
    PubMed         Abstract available
    
    

    
    Semin Oncol Nurs

54. BENTSEN L, Lund-Jacobsen T, Jakobsen CB, Larsen FM, et al
    Shared Decision-Making in Curative Uro-Oncology: A Systematic Review.
    Semin Oncol Nurs. 2026;42:152116.
    PubMed         Abstract available
    
    

    
    Transl Oncol

55. CHEN ST, Chang KS, Hou CP, Lin WY, et al
    WISP1 is the stromal-secreting oncoprotein via paracrine downregulation of NDRG1, KAI1, and Maspin in human bladder cancer cells.
    Transl Oncol. 2026;65:102680.
    PubMed         Abstract available
    
    

    
    Urol Oncol

56. CHEN Q, Wu R, Zhang C, Xie J, et al
    Efficacy and safety of tislelizumab plus intravesical chemotherapy in recurrent high-risk non-muscle-invasive bladder cancer: A retrospective single-center real-world study.
    Urol Oncol. 2026;44:110988.
    PubMed         Abstract available
    
    

    
    World J Urol

57. SCHERRER M, Brunaiova L, Furrer M, John H, et al
    How safe is teaching radical cystectomy? : Results from the prospective Swiss society of urology database.
    World J Urol. 2026;44:133.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.